Chromosome 11q13 amplification as a decision-making biomarker for anti-PD-1 immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma: a prospective cohort study

TL;DR

This study shows that patients with head and neck cancer without a specific genetic change (11q13 amplification) respond better to a type of immunotherapy called anti-PD-1, suggesting this genetic marker can help guide treatment decisions.

Contribution

The study prospectively validates 11q13 amplification as a biomarker for anti-PD-1 therapy in R/M HNSCC, offering a new decision-making tool for treatment selection.

Findings

Patients without 11q13 amplification had a 72.5% response rate to anti-PD-1 therapy.

Median progression-free survival was 14.3 months for non-amplified patients on anti-PD-1 therapy.

Overall survival for non-amplified patients was 38.2 months, outperforming other treatment groups.

Abstract

Anti-programmed cell death protein 1 (anti-PD-1) immunotherapy has shown efficacy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but current biomarkers have limitations in predicting immunotherapy response accurately. Chromosome 11q13 amplification, prevalent in HNSCC, has been associated with reduced efficacy of anti-PD-1 therapy. This study aims to prospectively evaluate 11q13 amplification as a biomarker for guiding first-line treatment in R/M HNSCC. We hypothesize that excluding patients with 11q13 amplification from anti-PD-1 therapy may enhance survival outcomes.

This single-institution prospective cohort study included previously untreated patients with R/M HNSCC. Based on 11q13 amplification status, non-amplified patients received PD-1 inhibitor monotherapy or combination therapy with chemotherapy, while amplified patients were treated with cetuximab and chemotherapy. Nedaplatin was used in place of cisplatin if necessary. Ten 11q13-amplified patients receiving anti-PD-1 therapy served as an external control group.

Between August 2020 and June 2023, 75 patients were enrolled prospectively, and an additional 10 patients with 11q13 amplification were included as an external control. Among R/M HNSCC patients without 11q13 amplification who received anti-PD-1-based therapy, the objective response rate (ORR) was 72.5%, with a median progression-free survival (PFS) of 14.3 months and an overall survival (OS) of 38.2 months. These survival outcomes were superior to those seen in other cohorts within this study and reported in other trials.

Our study suggests that 11q13 amplification status could serve as a valuable biomarker for first-line treatment decisions in R/M HNSCC. Patients without 11q13 amplification exhibited better responses to anti-PD-1 therapy, providing insights into optimizing treatment strategies.

Chinese Clinical Trial Registry identifier, ChiCTR2000035635.

Figures